A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chro
Completed
Janssen Sciences Ireland UC
Phase 1
The purpose of this study is to evaluate pharmacokinetics and safety data including serious
and other adverse events, physical examinations, vital signs, 12-lead electrocardiograms
(ECGs) and clinical laboratory results (including biochemistry, hematology, and urine).
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants
Completed
Janssen Research & Development, LLC
Phase 1
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics
(PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of
single doses from 25 milligram (mg) up to 600 mg, in fasted conditions.
A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Prob
Completed
Janssen Sciences Ireland UC
Phase 1
The main purpose of this study is to evaluate the effect of steady-state concentrations of
JNJ-56136379 on the single-dose pharmacokinetics (PK) of drospirenone and ethinylestradiol
(oral contraceptive [OC]) in healthy female participants and to evaluate the effect of
steady-state concentrations of JNJ-56136379 on the single-dose PK of midazolam (sensitive
probe substrate for CYP3A4) in healthy female participants.
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
Completed
Janssen Sciences Ireland UC
Phase 2
The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in
terms of changes in hepatitis B surface antigen (HBsAg) levels.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
